UDP glucuronosyltransferase family 2 member B7Genealiases: UDPGT 2B7 · UDPGT 2B9 · UDPGT2B7 · UDPGTH2 · UDPGTh-2 · UGT2B9
Q-omics provides the consensus-scored UGT2B7 profile across patient tissues and cancer cell-line models. UGT2B7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UGT2B7 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, UGT2B7 RNA expression shows 12,842 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where UGT2B7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UGT2B7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UGT2B7 survival associations across molecular data types. UGT2B7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UGT2B7 RNA expression–survival associations across cancer types. High UGT2B7 expression shows unfavorable associations in LUAD, STAD and PAAD, but favorable associations in KIRC, BLCA and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UGT2B7 RNA expression.
This table summarizes UGT2B7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UGT2B7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UGT2B7 shows lower tumor expression in KICH, LIHC, COAD, KIRP, BRCA and CHOL. The KICH box plot shows higher UGT2B7 RNA expression in normal versus tumor tissue (log2 FC = −7.027, t-test p < 0.001).
This table shows molecular features associated with UGT2B7 in patient tissues and cancer cell lines. In patient samples, UGT2B7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, UGT2B7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SKIN.
